243 related articles for article (PubMed ID: 23553594)
1. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections.
Lee YT; Tsao SM; Hsueh PR
Eur J Clin Microbiol Infect Dis; 2013 Sep; 32(9):1211-20. PubMed ID: 23553594
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests.
Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C
J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.
Liu B; Bai Y; Liu Y; Di X; Zhang X; Wang R; Wang J
J Chemother; 2015 Oct; 27(5):271-6. PubMed ID: 25068186
[TBL] [Abstract][Full Text] [Related]
4. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection.
Shin JA; Chang YS; Kim HJ; Kim SK; Chang J; Ahn CM; Byun MK
Yonsei Med J; 2012 Sep; 53(5):974-84. PubMed ID: 22869481
[TBL] [Abstract][Full Text] [Related]
6. A comparison of clinical and microbiological efficacy of antibiotic regimens against Acinetobacter baumannii.
Ackerman BH; Haith LR; Patton ML; Guilday RE; Reigart CL; Stair-Buchmann M
J Burn Care Res; 2013; 34(4):403-12. PubMed ID: 23237825
[TBL] [Abstract][Full Text] [Related]
7. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC
Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant
Niu T; Luo Q; Li Y; Zhou Y; Yu W; Xiao Y
Antimicrob Resist Infect Control; 2019; 8():52. PubMed ID: 30886705
[TBL] [Abstract][Full Text] [Related]
9. Colistin-tigecycline versus colistin-imipenem-cilastatin combinations for the treatment of Acinetobacter baumannii ventilator-acquired pneumonia: a prognosis study.
Chaari A; Pham T; Mnif B; Chtara K; Medhioub F; Baccouche N; Bahloul M; Hammami A; Bouaziz M
Intensive Care Med; 2015 Nov; 41(11):2018-9. PubMed ID: 26264246
[No Abstract] [Full Text] [Related]
10. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
11. In vitro effects of tigecycline in combination with colistin (polymyxin E) and sulbactam against multidrug-resistant Acinetobacter baumannii.
Ni W; Cui J; Liang B; Cai Y; Bai N; Cai X; Wang R
J Antibiot (Tokyo); 2013 Dec; 66(12):705-8. PubMed ID: 23981963
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis.
Dinc G; Demiraslan H; Elmali F; Ahmed SS; Metan G; Alp E; Doganay M
Chemotherapy; 2013; 59(5):325-9. PubMed ID: 24525528
[TBL] [Abstract][Full Text] [Related]
13. Observation of clinical efficacy of the cefoperazone/sulbactam anti-infective regimen in the treatment of multidrug-resistant Acinetobacter baumannii lung infection.
Wang Q; Huang M; Zhou S
J Clin Pharm Ther; 2022 Jul; 47(7):1020-1027. PubMed ID: 35285526
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.
Principe L; D'Arezzo S; Capone A; Petrosillo N; Visca P
Ann Clin Microbiol Antimicrob; 2009 May; 8():18. PubMed ID: 19460166
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.
Chuang YC; Cheng CY; Sheng WH; Sun HY; Wang JT; Chen YC; Chang SC
BMC Infect Dis; 2014 Feb; 14():102. PubMed ID: 24564226
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii clinical isolates.
Ricciardi R; Ricciardi AM; Danzi G
Infez Med; 2009 Dec; 17(4):236-9. PubMed ID: 20046104
[TBL] [Abstract][Full Text] [Related]
17. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii.
Ye JJ; Lin HS; Kuo AJ; Leu HS; Chiang PC; Huang CT; Lee MH
J Infect; 2011 Nov; 63(5):351-61. PubMed ID: 21846481
[TBL] [Abstract][Full Text] [Related]
18. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Ye JJ; Lin HS; Yeh CF; Wu YM; Huang PY; Yang CC; Huang CT; Lee MH
BMC Infect Dis; 2016 Aug; 16():374. PubMed ID: 27496018
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and Characterization of Integrons in Multidrug Resistant Acinetobacter baumannii in Eastern China: A Multiple-Hospital Study.
Chen J; Li H; Yang J; Zhan R; Chen A; Yan Y
Int J Environ Res Public Health; 2015 Aug; 12(8):10093-105. PubMed ID: 26308028
[TBL] [Abstract][Full Text] [Related]
20. Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome.
Kuo LC; Lai CC; Liao CH; Hsu CK; Chang YL; Chang CY; Hsueh PR
Clin Microbiol Infect; 2007 Feb; 13(2):196-198. PubMed ID: 17328733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
